EDX Medical Group - Service agreement with Royal Marsden NHS Trust

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

6 March 2025

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Group" or "Company")

EDX MEDICAL SIGNS MASTER SERVICES AGREEMENT WITH

THE ROYAL MARSDEN NHS FOUNDATION TRUST

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular disease and infectious diseases, announces today it has signed a master service agreement with The Royal Marsden NHS Foundation Trust ("The Royal Marsden").

Under the terms of the three-year agreement, EDX Medical will, as required, supply services to The Royal Marsden.

Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, commented: "I have always had the highest regard for the people and the work they do at The Royal Marsden and have run some significant cancer clinical trials there over the years. I am delighted EDX Medical has now been appointed as a supplier of diagnostic solutions and services to help serve the needs of one of the world's most eminent cancer hospitals."

The Board of directors of EDX Medical plc accepts responsibility for this announcement.

ENDS

Contacts

Notes for Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

EDX Medical conducts product development, validation and distribution to ISO 13485 and provides PCR services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

www.edxmedical.com